AU Patent

AU2017312102B2 — Therapeutic compounds useful for the prophylactic or therapeutic treatment of an HIV virus infection

Assigned to Gilead Sciences Inc · Expires 2020-03-05 · 6y expired

What this patent protects

The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): (Ia) (Ib) (IIa) (IIb) which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

USPTO Abstract

The present disclosure relates to a compound of formula (Ia), (Ib), (IIa), and (IIb): (Ia) (Ib) (IIa) (IIb) which are useful in the treatment of a Retroviridae viral infection including an infection caused by the HIV virus.

Drugs covered by this patent

Patent Metadata

Patent number
AU2017312102B2
Jurisdiction
AU
Classification
—
Expires
2020-03-05
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.